Previous 10 | Next 10 |
2023-11-01 08:34:25 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid Therapeutics for $30M Ligand Pharmaceuticals closes acquisition of assets of Novan For further det...
TZIELD is the first and only FDA approved treatment to delay the onset of Stage 3 type 1 diabetes Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it has acquired Tolerance Therapeutics, Inc. (“Tolerance Therapeutics”) for $20 million in cash. To...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will report third quarter 2023 financial results after the close of the U.S. financial markets on Wednesday, November 8, 2023, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a ge...
2023-10-18 11:05:36 ET More on Ligand Pharmaceuticals, Ovid Therapeutics, etc. Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand: Nothing Exciting Stands Out For further details see: Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid T...
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat Trans...
2023-10-03 17:46:09 ET More than 80 stocks were identified by Morgan Stanley as potentially having technical pressure due to tax loss selling. A Morgan Stanley U.S. Equity Strategy report, published on Monday, showed 81 stocks that could have performance pressures due to market selling ...
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual health was ...
2023-09-27 13:47:17 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals Incorporated 2023 Q2 - Results - Earnings Call Presentation Ligand Pharmaceuticals Incorporated (LGND) Q2 2023 Earnings Call Transcript Ligand spi...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has closed the transaction to acquire assets of Novan, Inc. (“Novan”) following the offer it made on July 17, 2023. On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board. “We are very ...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
FDA approval increases Ligand’s key commercial stage portfolio to 11 products Ligand is entitled to receive a low single-digit royalty on worldwide net sales of Ohtuvayre Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Verona Pharma plc...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...